{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:24:11Z","timestamp":1775856251273,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pimecrolimus 1% cream has already been proved to be an effective and safe alternative to treat seborrheic dermatitis. However, the treatment periods were inconstant in previous studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the comparative efficacy of pimecrolimus 1% cream with different regimens for the treatment of facial seborrheic dermatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Thirty patients with facial seborrheic dermatitis were enrolled and randomly distributed to three groups. Patients of Group 1 were treated with topical pimecrolimus cream 1% twice daily for 2 weeks and then a moisturizer cream twice daily for 2 weeks. Patients of Group 2 were treated with pimecrolimus cream 1% twice daily for 2 weeks and then once daily for another 2 weeks. Patients of Group 3 had a consecutive course of pimecrolimus cream 1% twice daily for 4 weeks. Objective symptoms, subjective symptoms, and dermatology life quality index (<jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>) were measured at weeks 0, 2, 4, and 6.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 4, the clinical severity scores of all three regimens significantly decreased (<jats:italic>P<\/jats:italic>&lt;.01). The improvement of total severity score in Group 3 was more remarkable than groups 1 and 2 (both <jats:italic>P<\/jats:italic>&lt;.05). This effect was maintained until the end of the study in Group 3. Life quality of all three groups was significantly improved at week 4 (<jats:italic>P<\/jats:italic>&lt;.001), while there was no statistical difference on the improvement of life quality among three groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We recommend pimecrolimus 1% cream could be applied twice a day for 4 weeks to treat seborrheic dermatitis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.12353","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T05:16:43Z","timestamp":1496812603000},"page":"90-94","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of different regimens of pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis"],"prefix":"10.1111","volume":"17","author":[{"given":"Juemin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology Huashan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-5667","authenticated-orcid":false,"given":"Chengfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leihong","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1","article-title":"Seborrheic dermatitis and dandruff: a comprehensive review","volume":"3","author":"Borda LJ","year":"2015","journal-title":"J Clin Investig Dermatol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.01.001"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/ecp.11.68","article-title":"Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials","volume":"5","author":"Ang\u2010Tiu CU","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"e_1_2_6_5_1","first-page":"207","article-title":"Pimecrolimus: a new treatment for seborrheic dermatitis","volume":"70","author":"Crutchfield CE","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06208.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.1066"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802286993"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-013-0960-8"},{"key":"e_1_2_6_10_1","first-page":"191","article-title":"Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk","volume":"30","author":"Rallis E","year":"2004","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.007"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01923.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802684692"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2007.22.5.868"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.01.011"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjocd.12353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.12353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T22:01:31Z","timestamp":1695765691000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.12353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/jocd.12353"],"URL":"https:\/\/doi.org\/10.1111\/jocd.12353","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]}}}